Current studentsExisting staffContact us
 

Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials

Simple item page
dc.contributor.authorGrossmann, M.
dc.contributor.authorHoermann, R.
dc.contributor.authorWittert, G.
dc.contributor.authorYeap, B.
dc.date.issued2015
dc.description.abstractContext: The effects of testosterone treatment on glucose metabolism and other outcomes in men with type 2 diabetes (T2D) and/or the metabolic syndrome are controversial. Objective: To perform a systematic review and meta-analysis of placebo-controlled double-blind randomized controlled clinical trials (RCT) of testosterone treatment in men with T2D and/or the metabolic syndrome. Data sources: A systematic search of RCTs was conducted using Medline, Embase and the Cochrane Register of controlled trials from inception to July 2014 followed by a manual review of the literature. Study selection: Eligible studies were published placebo-controlled double-blind RCTs published in English. Data extraction: Two reviewers independently selected studies, determined study quality and extracted outcome and descriptive data. Data synthesis: Of the 112 identified studies, seven RCTs including 833 men were eligible for the meta-analysis. In studies using a simple linear equation to calculate the homeostatic model assessment of insulin resistance (HOMA1), testosterone treatment modestly improved insulin resistance, compared to placebo, pooled mean difference (MD) −1·58 [−2·25, −0·91], P < 0·001. The treatment effect was nonsignificant for RCTs using a more stringent computer-based equation (HOMA2), MD −0·19 [−0·86, 0·49], P = 0·58). Testosterone treatment did not improve glycaemic (HbA1c) control, MD −0·15 [−0·39, 0·10], P = 0·25, or constitutional symptoms, Aging Male Symptom score, MD −2·49 [−5·81, 0·83], P = 0·14). Conclusions: This meta-analysis does not support the routine use of testosterone treatment in men with T2D and/or the metabolic syndrome without classical hypogonadism. Additional studies are needed to determine whether hormonal interventions are warranted in selected men with T2D and/or the metabolic syndrome.
dc.description.statementofresponsibilityMathis Grossmann, Rudolf Hoermann, Gary Witter and Bu B. Yeap
dc.identifier.citationClinical Endocrinology, 2015; 83(3):344-351
dc.identifier.doi10.1111/cen.12664
dc.identifier.issn0300-0664
dc.identifier.issn1365-2265
dc.identifier.orcidWittert, G. [0000-0001-6818-6065]
dc.identifier.urihttp://hdl.handle.net/2440/99845
dc.language.isoen
dc.publisherWiley-Blackwell
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1024139
dc.rights© 2014 John Wiley & Sons Ltd
dc.source.urihttps://doi.org/10.1111/cen.12664
dc.subjectMetabolic syndrome
dc.titleEffects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications